Obesity drug market tipped to slow

Low efficiency and negative side effects have an adverse effect on the sale and development of drugs against obesity, according to a forecast by Datamonitor.
Click here! Quantcast

The analyst firm business argued that professionals in health care always regarded obesity as the result of lifestyle choices that could be better managed through diet and exercise rather than drugs.

The market situation of weight loss was also hampered by the revelations of side effects caused by major players, Datamonitor said.

Drug sibutramine weight loss - marketed in Australia as Ectiva or Reductil - was suspended across the European Union in January after regulators deemed it caused increased risk of cardiovascular events.

"The sector continues to be plagued by low efficiency, the profiles of side effects and lack of reimbursement by providers of health care," chief analyst of health care at Datamonitor, Dr Nick Karachalias said .

"There is a certain irony that obesity as a major driver of type 2 diabetes growth of the pharmaceutical market, will not be processed on a large scale by the pharmaceutical market. Diets and industry personnel fitness are just too big. "

However, Datamonitor predicts that the market for drugs to manage diabetes could double in the next ten years, with the dipeptidyl peptidase IV (DPP-IV) inhibitors and glucagon-like-1 (GLP-1) agonists winners.

"Having benefited from a significant period of time that the DPP-IV only in the market, Januvia (sitagliptin) continue to be the market leader, despite having little clinical differentiation from other molecules in the classroom," Dr. Karachalias said.